Eiger BioPharmaceuticals Inc (Nasdaq: EIGR), a US-based company focused on the development and commercialisation of targeted therapies for serious rare and ultra-rare diseases, announced on Friday that David Apelian will step down as the company's chief operating officer and executive medical officer, effective 14 June 2019.
Dr Apelian is to become the chief executive officer at a private biotech company. He will remain actively engaged with Eiger and will continue to serve on Eiger's board of directors. Dr Apelian will consult with the company to assist with the transition.
David Cory, chief executive officer at Eiger, said, 'I want to thank David for his service to Eiger, particularly in leading the Company's hepatitis delta virus (HDV) program. David played an important role in negotiating Phase 3 D-LIVR study design and endpoints with FDA, allowing Eiger to initiate the first-ever Phase 3 study in HDV. David has built a strong clinical team, and Eiger is poised to execute across all programs. I wish him well in his new position and look forward to continuing to work with him on our board.'
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT